RLYB Share Price Performance
Recent RLYB News & Updates
No updates
Rallybio Corporation Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.16
- Gross Margin
- -3,944.34%
- Net Profit Margin
- -5,682.19%
- Debt/Equity Ratio
- 0%
Rallybio Corporation Competitors
About RLYB
- Founded
- 2018
- Employees
- 24
- CEO
- WebsiteView website
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
U.S. Market Performance
- 7 Days: -0.3%
- 3 Months: 14.2%
- 1 Year: 15.7%
- Year to Date: 8.0%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.1%. As for the longer term, the market has risen 16% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading